A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza (AVX502-003)
Primary Purpose
Influenza
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
AVX502
AVX502
Placebo
Placebo
Sponsored by
About this trial
This is an interventional prevention trial for Influenza focused on measuring Influenza, Flu, A/Wyoming/03/2003, Alphavirus
Eligibility Criteria
Inclusion Criteria:
- Age 65 years of age or older
- Good general health without significant physical examination findings or clinically significant abnormal laboratory results
- Available to participate for entire study period
- Acceptable laboratory parameters
- Willingness to have blood stored for up to 10 years for use in additional assays to evaluate immune responses to influenza or the alphavirus vector if such assays become available
- Willingness to refrain from donating blood while participating in the study
- Willingness to delay receipt of 2008-2009 licensed influenza vaccination until after completing study visit 6 procedures (study week 8)
- Signed inform consent obtained before screening and before enrollment
Exclusion Criteria:
- Venous access deemed inadequate for th phlebotomy demands of the study
- Receipt of any other vaccine within 30 days prior to enrollment
- Use of any investigational agent within 30 days prior to enrollment
- Receipt of immunoglobulin or other blood products within 60 days prior to enrollment
- Use of cytotoxic medications within 6 months prior to enrollment
- Use of systemic corticosteroids within 6 months prior to enrollment (except that participants who have completed a course of prednisone, at up to 20 mg per day for up to 7 days, at least 1 month prior to enrollment are eligible for enrollment)
- History of serious adverse reactions to any vaccines, including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, or abdominal pain
- History of autoimmune disease or splenectomy
- History of malignancy within the last 3 years (except that participants with a diagnosis of basal cell carcinoma of the skin are eligible for enrollment)
- Psychiatric condition that may interfere with the ability to comply with the protocol requirements or to understand informed consent. Specifically excluded are persons with history of psychosis within the past 3 years or history of suicidal attempt or gesture within the past 3 years.
- History of medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months
- Any condition which leads the investigator to believe that the particpant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for further participation.
Sites / Locations
- Johnson County Clin-Trials
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Placebo Comparator
Placebo Comparator
Arm Label
T1
T2
C1
C2
Arm Description
Outcomes
Primary Outcome Measures
Evaluate the safety of AVX502 in healthy adult volunteers 65 years of age or older via the frequency of systemic reactogenicity events, local vaccine reactions and Adverse Events
Secondary Outcome Measures
Evaluate the immunogenicity of AVX502 in healthy adult volunteers 65 years of age and older via serum antibody concentration
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00706732
Brief Title
A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza
Acronym
AVX502-003
Official Title
A Single-Site, Phase I/II, Double Blinded, Safety and Immunogenicity Trial of an Alphavirus Replicon Vaccine Expressing Influenza A/Wyoming/03/2003 Hemagglutinin (AVX502) in Adult Volunteers 65 Years of Age or Older
Study Type
Interventional
2. Study Status
Record Verification Date
July 2012
Overall Recruitment Status
Completed
Study Start Date
June 2008 (undefined)
Primary Completion Date
September 2008 (Actual)
Study Completion Date
March 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AlphaVax, Inc.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study is to evaluate the safety of the vaccine and the immune response to the vaccine in healthy adult volunteers 65 years of age or older. Volunteers will be assigned by randomization to receive either the vaccine or an inactive substance (placebo) by injections in the arm on two occasions over one month. The study will last approximately 10 months and will have a total of 7 visits.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Influenza
Keywords
Influenza, Flu, A/Wyoming/03/2003, Alphavirus
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
T1
Arm Type
Active Comparator
Arm Title
T2
Arm Type
Active Comparator
Arm Title
C1
Arm Type
Placebo Comparator
Arm Title
C2
Arm Type
Placebo Comparator
Intervention Type
Biological
Intervention Name(s)
AVX502
Intervention Description
2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
Intervention Type
Biological
Intervention Name(s)
AVX502
Intervention Description
2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
2 doses of placebo given at T=0 and T=4 weeks via the IM route
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
2 doses of placebo given at T=0 and T=4 weeks via the SC route
Primary Outcome Measure Information:
Title
Evaluate the safety of AVX502 in healthy adult volunteers 65 years of age or older via the frequency of systemic reactogenicity events, local vaccine reactions and Adverse Events
Time Frame
28 weeks
Secondary Outcome Measure Information:
Title
Evaluate the immunogenicity of AVX502 in healthy adult volunteers 65 years of age and older via serum antibody concentration
Time Frame
4 weeks after second dose of vaccine
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age 65 years of age or older
Good general health without significant physical examination findings or clinically significant abnormal laboratory results
Available to participate for entire study period
Acceptable laboratory parameters
Willingness to have blood stored for up to 10 years for use in additional assays to evaluate immune responses to influenza or the alphavirus vector if such assays become available
Willingness to refrain from donating blood while participating in the study
Willingness to delay receipt of 2008-2009 licensed influenza vaccination until after completing study visit 6 procedures (study week 8)
Signed inform consent obtained before screening and before enrollment
Exclusion Criteria:
Venous access deemed inadequate for th phlebotomy demands of the study
Receipt of any other vaccine within 30 days prior to enrollment
Use of any investigational agent within 30 days prior to enrollment
Receipt of immunoglobulin or other blood products within 60 days prior to enrollment
Use of cytotoxic medications within 6 months prior to enrollment
Use of systemic corticosteroids within 6 months prior to enrollment (except that participants who have completed a course of prednisone, at up to 20 mg per day for up to 7 days, at least 1 month prior to enrollment are eligible for enrollment)
History of serious adverse reactions to any vaccines, including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, or abdominal pain
History of autoimmune disease or splenectomy
History of malignancy within the last 3 years (except that participants with a diagnosis of basal cell carcinoma of the skin are eligible for enrollment)
Psychiatric condition that may interfere with the ability to comply with the protocol requirements or to understand informed consent. Specifically excluded are persons with history of psychosis within the past 3 years or history of suicidal attempt or gesture within the past 3 years.
History of medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months
Any condition which leads the investigator to believe that the particpant cannot comply with the protocol requirements or that may place the participant at an unacceptable risk for further participation.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Olmsted, Ph.D.
Organizational Affiliation
AlphaVax, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Johnson County Clin-Trials
City
Lenexa
State/Province
Kansas
ZIP/Postal Code
66219
Country
United States
12. IPD Sharing Statement
Links:
URL
http://www.alphavax.com
Description
AlphaVax, Inc.
URL
http://www.jcct.com
Description
Johnson County Clin-Trials
Learn more about this trial
A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza
We'll reach out to this number within 24 hrs